Number of patients | 91 |
Median age, years (range) | 45 (16-75) |
Male | 44 (48.4) |
Female | 47 (51.6) |
Prior therapy with interferon-α | 29 |
Cytogenetic abnormalities in Ph-negative cells, no. (%) | 5 (5.5%) |
Time from initiation of imatinib to CCyR (months) Median (range) | 7 (6-50) |
Time from initiation of imatinib to MMR (months) Median (range) | 18 (9-65) |
Time from initiation of imatinib to CMR (months) Median (range) | 33 (5-78) |
Time from achievement of CCyR to last evaluation (months) Median (range) | 57 (24-95) |
Time from achievement of MMR to last evaluation (months) Median (range) | 36 (19-46) |
Time from achievement of CMR to last evaluation (months) Median (range) | 22 (6-49) |